About Tektin-3
Tektin-3 (TEKT3) is a protein
from Homo sapiens identified by UniProt accession
Q9BXF9, 490 residues long.
MolForge cross-references it against 0 known binders and
79 disease associations.
Target properties
| Protein name | Tektin-3 |
|---|
| UniProt accession | Q9BXF9 |
|---|
| Gene | TEKT3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 490 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (79)
Diseases linked to this target (Open Targets).
- hemoglobin measurement · score 0.18
- protein measurement · score 0.15
- erythrocyte count · score 0.13
- hematocrit · score 0.13
- azoospermia · score 0.10
- response to vaccine · score 0.10
- lymphocyte count · score 0.10
- male infertility with teratozoospermia due to single gene mutation · score 0.09
- diet measurement · score 0.08
- resting heart rate · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9BXF9-F1 | alphafold | PREDICTED | 85.86 | — |
Amino-acid sequence (490 residues)
MERVGCTLTT TYAHPRPTPT NFLPAISTMA SSYRDRFPHS NLTHSLSLPW RPSTYYKVAS NSPSVAPYCT RSQRVSENTM LPFVSNRTTF FTRYTPDDWY RSNLTNYQES NTSRHNSEKL RVDTSRLIQD KYQQTRKTQA DTTQNLGERV NDIGFWKSEI IHELDEMIGE TNALTDVKKR LERALMETEA PLQVARECLF HREKRMGIDL VHDEVEAQLL TEVDTILCCQ ERMKLHLDKA IAQLAANRAS QHELEKDLSD KQTAYRIDDK CHHLRNTSDG VGYFRGVERV DATVSVPESW AKFTDDNILR SQSERAASAK LRDDIENLLV VTANEMWNQF NKVNLSFTNR IAETADAKNK IQTHLAKTLQ EIFQTEMTIE SIKKAIKDKT AFLKVAQTRL DERTRRPNIE LCRDMAQLRL VNEVHEVDDT IQTLQQRLRD AEDTLQSLVH IKATLEYDLA VKANSLYIDQ EKCMSMRKSY PNTLRLVGFC
Explore Tektin-3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets